Health Care [ 5/12 ] | Biotechnology [ 30/73 ]
NASDAQ | Common Stock
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials.
The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye.
It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases.
The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | -0.40 Increased by +13.04% | -0.50 Increased by +20.00% |
| May 5, 25 | 1.90 Increased by +433.33% | -0.09 Increased by +2.20 K% |
| Mar 24, 25 | -0.18 Increased by +70.00% | -0.53 Increased by +66.05% |
| Nov 5, 24 | -0.47 Increased by +14.71% | -0.53 Increased by +11.49% |
| Aug 7, 24 | -0.46 Increased by +33.33% | -0.56 Increased by +17.86% |
| May 6, 24 | -0.57 Decreased by -7.55% | -0.61 Increased by +6.56% |
| Mar 25, 24 | -0.60 Increased by +7.69% | -0.63 Increased by +4.76% |
| Nov 7, 23 | -0.55 Increased by +16.67% | -0.63 Increased by +12.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 13.82 M Increased by +186.01% | -23.48 M Increased by +8.61% | Decreased by -169.96% Increased by +68.05% |
| Mar 31, 25 | 158.57 M Increased by +3.66 K% | 112.88 M Increased by +527.99% | Increased by +71.19% Increased by +111.38% |
| Dec 31, 24 | 22.61 M Increased by +707.07% | -10.48 M Increased by +61.12% | Decreased by -46.35% Increased by +95.18% |
| Sep 30, 24 | 4.89 M Increased by +47.94% | -26.43 M Decreased by -7.69% | Decreased by -540.05% Increased by +27.21% |
| Jun 30, 24 | 4.83 M Increased by +294.72% | -25.70 M Increased by +16.18% | Decreased by -531.88% Decreased by -143.05% |
| Mar 31, 24 | 4.22 M Decreased by -18.17% | -26.37 M Decreased by -44.14% | Decreased by -625.57% Decreased by -76.15% |
| Dec 31, 23 | 2.80 M Decreased by -14.29% | -26.96 M Decreased by -22.28% | Decreased by -962.10% Decreased by -42.65% |
| Sep 30, 23 | 3.31 M Increased by +13.87% | -24.54 M Decreased by -1.92% | Decreased by -741.90% Increased by +10.49% |